Product Category

Chemicals & Pharmaceuticals > >

Chronic Obstructive Pulmonary Disease Drug(Pd No. : 3128378)

(Updated : 05/13/2019)
product information
Model Nm Pd No. : 3078673
HS CODE 300490
Keywords Chronic,Obstructive,Pulmonary,Disease,Drug
Seller ID rachel2019
  • twitter
  • facebook

[Target patients]

COPD patients are classified based on their degree of severity - Mild (Stage 1), Moderate (Stage 2), Severe (Stage 3), Very severe (Stage 4). The ultimate and primary goal of treatments is to prevent exacerbation of COPD. For such purpose, long term safety and prevention the development of resistance should be secured. None of the existing

drugs have been proven to stop the disease progression from Stage 1 or 2 to Stage 3 or 4. YPL-001 is for stage 2 or 3 patients to prevent COPD exacerbation.


Yungjin has completed Phase 1a (Single Ascending Dose Study) and 1b study (Multiple Ascending Dose Study). The IND and IRB have been done for Phase IIa and currently patients recruiting are ongoing.

Company Information

company information
Contact Person KIM YOON KYUNG
Company Yungjin Pharm. Co., Ltd
Homepage ,
Tel . Fax
Biz. Type Manufacturing and trade Est. Year -
Employees 501~

Other Products from [ rachel2019 ] (1)

View all
Related Business Event List
Convention on Pharmaceutical Ingredients Worldwide 2019 2019-11-05 ~ 2019-11-07
Int 2019-07-03 ~ 2019-07-05


  • - Please leave a detailed inquiry to get an accurate reply from the Korean seller.
To Yungjin Pharm. Co., Ltd
CC  You are able to send one CC-mail ONLY
Message Tips to receive a better response:
 •  Introduce yourself and your company
 •  Provide detailed requirements(for example : order quantity)
 •  Mention what you want to know from seller (for example : MOQ delivery lead time, unit price)

Your message must be between 20-8000 characters
Quantity  Please enter purchase quantity for a price quotation